AVEO Oncology

Vertex Pharmaceuticals Incorporated is a global biotechnology company engaged in the discovery and development of breakthrough small molecule drugs for serious diseases. The company commercializes its products independently and in collaboration with major pharmaceutical companies. Vertex s product line includes drugs for viral diseases, inflammation, autoimmune diseases and cancer. Vertex is developing treatments for cancer, HIV and AIDS and pain through collaborations with some of the leading pharmaceutical companies. The company has collaborations with Cystic Fibrosis Foundation Therapeutics, GlaxoSmithKline, Kissei Pharmaceutical, Merck & Co., Mitsubishi Pharma Corporation and Novartis Pharma. Vertex co-promotes the HIV and AIDS protease inhibitor, Lexiva, with GlaxoSmithKline. Vertex Pharmaceuticals Incorporated is located in Cambridge, Mass.

Opexa Therapeutics is a biotechnology company that specializes in the development of patient-specific cellular therapies for the treatment of autoimmune diseases, such as multiple sclerosis and diabetes. It offers Tovaxin, which is a vaccine for early relapsing multiple sclerosis. The company also offers an adult stem cell program that enables the production of multipotent cells generated from patients white blood cells and provides means to differentiate these stem cells into other tissue types. Opexa Therapeutics offers solutions that minimize the threat of treatment rejection. It operates clinical advisory boards for multiple sclerosis and diabetes that take care of the supervision of related procedures. The company provides products to target individual s disease progression and modification.

Syntonix Pharmaceuticals is engaged in the discovery and development of novel, long-acting, proprietary therapeutic products that utilize the company s proprietary Fc-fusion proteins and other engineered ligands that bind to specific Fc receptors. These technologies, including the Transceptor drug-delivery platform, are designed to use the body s natural protection of antibodies against premature destruction and for the transport of antibodies across cell barriers. The company focuses on using these technologies to create next-generation treatments for chronic diseases such as hemophilia, anemia and autoimmune disorders. It develops selected products for specialty indications and evaluates and commercializes other products through partnerships. The company occupies a 25,000-square-foot laboratory facility that includes a clinical manufacturing suite. Syntonix Pharmaceuticals is headquartered in Waltham, Mass.